Novartis AG ADR (NVS)vsOcular Therapeutix Inc (OCUL)

NVS

Novartis AG ADR

NYSE

$148.38

-0.99%

HEALTHCARE · Cap: $273.77B

OCUL

Ocular Therapeutix Inc

NASDAQ

$8.25

-6.25%

HEALTHCARE · Cap: $1.96B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 108624% more annual revenue ($56.58B vs $52.04M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NVS

Hold

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

OCUL

Avoid

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 6.5

Piotroski: 3/9Altman Z: 0.66

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Intrinsic value data unavailable for OCUL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

OCUL1 strengths · Avg: 9.0/10

Debt/EquityHealth

0.149/10

Conservative balance sheet, low leverage

Areas to Watch

NVS4 concerns · Avg: 2.8/10

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.223/10

Elevated debt levels

PEG RatioValuation

3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

OCUL4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.8%4/10

0.8% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$1.96B3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : OCUL

The strongest argument for OCUL centers on Debt/Equity.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : OCUL

The primary concerns for OCUL are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

NVS profiles as a declining stock while OCUL is a value play — different risk/reward profiles.

OCUL carries more volatility with a beta of 0.90 — expect wider price swings.

OCUL is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 25/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs MRK NVS vs AZN OCUL vs LLY OCUL vs JNJ OCUL vs ABBV OCUL vs MRK OCUL vs AZN

Want to dig deeper into these stocks?

Full NVS Analysis →Full OCUL Analysis →